文献速递核素与放射性配体治疗肿瘤 PET/CT

放射性配体治疗剂量测定新需求:神经内分泌肿瘤大队列可行性验证

Emerging need of dosimetry in radioligand therapy: a feasible method tested in a large cohort of patients affected by neuroendocrine neoplasms.
PubMed 文献 · EJNMMI Res · 2026-04-21

该方法可行且易临床实施,可辅助治疗决策。

要点

  • 基于三时间点SPECT/CT的简化剂量学方法在神经内分泌肿瘤患者中可行。
  • 肿瘤单位活度吸收剂量变异大,剂量学可辅助治疗决策。

核心结论

  • 所提出的简化剂量学方法可行且易于临床实施。
  • 剂量学是 useful 临床工具,可指导患者接受联合核素治疗或多程治疗以改善结局。

研究设计与样本

  • FENET-2016方案含MONO方案(5周期177Lu-DOTATOC)和DUO方案(3周期177Lu-DOTATOC与2周期90Y-DOTATOC交替)。

主要发现

  • 报告了危及器官和肿瘤的单位给药活度吸收剂量、累积吸收剂量,以及危及器官的生物有效剂量。
  • 无病例报告骨髓累积吸收剂量超过2 Gy。
  • 观察到肿瘤单位活度吸收剂量高度变异。

关键数值与推荐

  • 骨髓累积吸收剂量超过2 Gy:0例。

临床怎么用

  • 该简化剂量学方法可在临床常规中实施,用于评估肾、骨髓和肿瘤的吸收剂量。
  • 剂量学结果可帮助临床医生引导患者选择联合核素治疗或多程治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radioligand therapy is an important treatment option for neuroendocrine neoplasms. Although the use of internal dosimetry is recommended, its application in clinical routine is not widespread. This study aims to propose and evaluate a feasible method for determining the absorbed doses to organs at risk and tumour lesions in a large cohort of neuroendocrine neoplasm patients. Eighty patients who were treated as part of the FENET-2016 trial were enrolled in this study prospectively. The FENET-2016 protocol is based on two therapeutic schemes: a MONO therapy, consisting of five administrations (therapeutic cycles) of 177Lu-DOTATOC and a DUO therapy, consisting of three cycles of 177Lu-DOTATOC alternating with two cycles of 90Y-DOTATOC. A simplified method based on three-time-point SPECT/CT was first validated on a small cohort of patients and was then applied to all the eighty patients enrolled in the study to assess dosimetric evaluation for the organs at risk (kidneys, bone marrow, and tumours). RESULTS: Sixty-nine patients underwent a complete dosimetric evaluation. Absorbed doses per administered activity and cumulative absorbed doses were reported for organs at risk and tumours, as well as biologically effective doses for organs at risk. The results of this study are consistent with published data from other groups. The cumulative absorbed dose to the kidneys exceeded the threshold reported in the literature in ten cases out of sixty-nine cases, while no cases of a cumulative absorbed dose exceeding 2 Gy to the bone marrow were reported. High variability in tumour absorbed dose per unit activity was observed. CONCLUSIONS: The proposed simplified dosimetric approach is feasible and easy to implement in clinical practice. This study demonstrated that dosimetry is a useful clinical tool, as it enables clinicians to guide patients towards combined radionuclide treatment or multiple treatments, which could improve patient outcomes. CLINICAL TRIAL REGISTRATION: - EU Clinical Trials Register, EUDRACT Id: 2016-005129-35, 22 February 2018. TRIAL REGISTRATION: EUDRACT 201,600,512,935, Registered 22 February 2018, https//www.clinicaltrialsregister.eu/ctrsearch/search? query=2016-005129-35.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Longo M, Tonini E, Di Domenico G, et al. Emerging need of dosimetry in radioligand therapy: a feasible method tested in a large cohort of patients affected by neuroendocrine neoplasms. EJNMMI Res. 2026. PMID: 42014664. doi:10.1186/s13550-026-01442-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。